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The human immunodeficiency virus type 1 (HIV-1) gp41 plays an important role in mediating the fusion of HIV with host cells. During
the fusion process, three N-terminal helices and three C-terminal helices pack in an anti-parallel direction to form a six-helix bundle. X-ray
crystallographic analysis of the gp41 core demonstrated that within each coiled-coil interface, there is a deep and large pocket, formed by a
cluster of residues in the N-helix coiled coil. In this report, we systematically analyzed the role of seven conserved residues that are either
lining or packing this pocket on the infectivity and interhelical interaction using novel approaches. Our results show that residues L568,
V570, W571, and K574 of the N-helix that are lining the side chain and right wall of the pocket are important for establishing a productive
infection. Mutations V570A and W571A completely abolished replication, while replication of the L568A and K574A mutants was
significantly attenuated relative to wild type. Similarly, residues W628, W631, and I635 of the C-helix that insert into the pocket are essential
for infectivity. The impaired infectivity of these seven mutants is in part attributed to the loss in binding affinity of the interhelical interaction.
Molecular modeling of the crystal structure of the coiled coil further shows that alanine substitution of those residues disrupts the
hydrophobic interaction between the N- and C-helix. These results suggest that the conserved residues in the coiled coil domain play a key
role in HIV infection and this coiled-coil pocket is a good target for development of inhibitors against HIV. In addition, our data indicate that
the novel fluorescence polarization assay described in this study could be valuable in screening for inhibitors that block the interhelical
interaction and HIV entry.
D 2004 Elsevier Inc. All rights reserved.
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Human immunodeficiency virus (HIV) is an enveloped
retrovirus that causes AIDS. As drug resistance renders
current drugs less useful to patients, other targets are being
explored (Hazuda et al., 2000; Kilby et al., 1998; Strizki et
al., 2001). Of them, gp41 serves as an important target for
the development of novel HIV fusion inhibitors because it0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2004.08.025
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E-mail address: Hongmei.Mo@abbott.com (H. Mo).plays an important role in the fusion of HIV with host cells.
In the infection process, gp120/gp41 binds to cell surface
receptors (CD4 and one of the co-receptors, such as CCR5
or CXCR4) (Berger et al., 1999; Wyatt and Sodroski,
1998), causing a series of conformational changes in the
gp120/gp41 oligomer (Eckert and Kim, 2001). During this
process, three N-terminal helices form a trimeric coiled-coil
bundle, and three C-terminal helices pack in the reverse
direction into three hydrophobic grooves on the surface of
the coiled coil (Lu et al., 2001; Marti et al., 2004; Yang et
al., 2002). This conformational change allows the fusion of
membranes to occur (Binley and Moore, 1997; Chan and
Kim, 1998).04) 319–327
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terminal peptide such as T20, which binds in the N-helix of
gp41, have been shown to be effective in reducing the viral
load in HIV-1-infected patients (Kilby et al., 1998). Some
evidence suggested that this peptide acts in a dominant-
negative manner by binding to the N-terminal coiled-coil
region of gp41 in its prehairpin intermediate state, therefore
interfering with its transition to the fusion-active six-helix
bundle structure (Chan and Kim, 1998; Chen et al., 1993;
Lu et al., 1995; Wild et al., 1994), thereby validating the
pocket as a potential target for the development of novel
inhibitors. However, the use of T20 widely in patients is
limited by the lack of oral bioavailability and high cost of
production. Alternatively, it would be highly desirable if an
orally bioavailable small molecule drug could be identified
that prevents HIV-1 fusion.
The crystal structure of the gp41 core demonstrated that
within each coiled-coil interface is a deep and large pocket
(~16-2 long, ~7-2 wide, and 5–6-2 deep), with an internal
volume of roughly 400 23 that could be filled by a smallFig. 1. Core structure of the HIV-1 gp41 envelope glycoprotein. (A) Schematic rep
are shown above the N- and C-terminal heptad-repeat region in this linear represe
The residues are numbered according to their positions in HXB2 gp160. (B) Relat
the N-helix coiled coil. The three residues of C-helix (W628, W631, and I635) are
L568/W571 and V570/K574 are lining the right wall and the side chain of the cmolecule inhibitor. This pocket is formed by 11 residues
(L565, L566, L568, T569, V570, W571, G572, I573, K574,
L576, and Q577) of the N-helix coiled coil (Chan et al.,
1997; Eckert et al., 1999). Of these 11 residues, four
residues L568, V570, W571, and K574 lining the right wall
or side chain of the pocket make an extensive interaction
with the three residues of the C-helix (W628, W631, and
I635) that insert into this pocket (Figs. 1A, B). In addition,
each of these seven residues is highly conserved (no
substitution at any of these seven positions among the 70
Clade B HIV sequences from the Los Alamos database).
Therefore, it is of fundamental importance to understand the
role of these seven amino acids on the infectivity and the
interhelical interactions.
Several reports have described the effects of individual
substitutions of six out of seven residues (L568, V570,
W571, W628, W631, and I635) on the fusion activity and/
or thermal stability (Cao et al., 1993; Ji et al., 1999; Lu et
al., 2001; Wang et al., 2002; Weng and Weiss, 1998; Weng
et al., 2000). In those studies, either a cell–cell fusionresentation of gp41. The amino acid sequences of the N36 and C34 peptides
ntation of gp41. Amino acids mutated to alanine in this study are indicated.
ionship of the seven residues studied with the deep cavity on the surface of
drawn against the surface representation of a part of the N-helix coiled coil.
avity, respectively.
Fig. 2. Effects of the mutations in the gp41 coiled coil on infectivity in a
multiple-round replication assay. Supernatants from transfected 293-T cells
harvested at the peak of p24 production were normalized for p24 activity
and used to infect MT4 cells. p24 levels were measured every 3 days for 11
days. The wild type pNL4-3 was included as control. Data represent results
from at least two independent transfections/infections, and triplicates for
each mutant were analyzed. All seven mutants except L568A and K574A
had p24 levels b10 pg/ml.
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for assessing the ability of the mutant envelope to mediate
cell–cell fusion or viral entry. However, others reported
that the sensitivity between the cell–cell fusion assay and
the single-cycle complementation assay differed, and both
assays have a limited sensitivity compared to the standard
multiple round replication assay (Cao et al., 1993; Chen et
al., 1998; Piller et al., 2000). Furthermore, the results from
those studies are difficult to compare because they differed
in the choice of envelope expression system, the cell lines,
and assays used (Cao et al., 1993; Ji et al., 1999; Lu et al.,
2001; Wang et al., 2002; Weng and Weiss, 1998; Weng et
al., 2000). While some reports claimed that specific
attachment sites appear to be required for proper gp41
expression and folding (Dash et al., 1994; Fenouillet et al.,
1993), to our knowledge, there has been no report on
direct examination of the effects of the above six residues
in the context of the entire HIV genome on HIV
infectivity. In addition, the function of residue K574 has
never been studied. Furthermore, how these seven residues
would affect the direct binding between the N- and C-helix
and what the relationship is between the interhelical
binding and the infectivity has not been addressed.
In this study, we examined the effect of each of the
above seven residues (L568, V570, W571, K574, W628,
W631, and I635) on HIV infectivity using a multiple-round
of replication assay. In addition, we describe a novel highly
sensitive fluorescence polarization (FP) assay that allowed
us to measure the in vitro affinity of mutant-C-peptide
binding to wild-type MBP-N-helix protein or wild-type-C-
peptide binding to mutant-N-helix protein. The effect of
the mutations on the interhelical interaction was assessed
using this novel binding assay and molecular modeling.
Our results provide direct evidence of the importance of
these seven residues for HIV infectivity and interhelical
interaction.Results
Residues comprising the cavity and inserting into the cavity
are essential for viral replication
The mutations introduced into the C- and N-helix of gp41
from HIV-1 pNL4-3 are depicted in Figs. 1A, B. These
residues were chosen for analysis because they are highly
conserved and are involved in an extensive interaction
between N- and C-helix, indicating their importance for HIV
entry. The effects on viral replication of mutations at these
residues were assessed in a multiple rounds of infectivity
assay. Supernatants from transfected 293-T cells, normalized
for p24 activity, were used to infect the T-cell line MT4 cells
to determine the ability of mutants to establish a productive
infection. The production of p24 was determined every 3
days for 11 days. As shown in Fig. 2, viruses containing
mutations W628A, W631A, or I635A completely abolishedreplication, as the p24 levels were b10 pg/ml during 11 days
of culture. Similarly, mutants V570A andW571Aviruses did
not replicate at all. The replication of the other two mutant
viruses L568A and K574A was also impaired compared to
the wild-type virus. The peak p24 levels of these two mutants
were at least two orders of magnitude lower than that of the
parental WT pNL4-3 although each was able to establish a
productive infection. These results suggested that the above
three residues in the C-helix that bind to residues in the
cavity and the four residues in the N-helix forming the cavity
are essential for viral replication.
Binding assay
A novel homogeneous fluorescence polarization assay
was developed to determine the binding affinities of the
interaction of MBP-N-helix, or its mutants with the
corresponding C-helix peptides. This assay allows us to
directly examine the level of loss of affinity in the
interhelical interaction of the mutants. We first established
the affinity (Kd) for the interaction of the Cy5.5-25-mer with
MBP-N-helix to be 154 nM (Table 1). To determine if this
interaction was attributed to a specific interaction rather than
an adventitious interaction of the fluorophore with the
protein, we successfully competed this binding with two
related peptide C-25-mers that were known to bind to the N-
helix. The Ki was calculated to be 226 nM, which was
consistent with the 154 nM Kd that was determined for the
direct interaction of MBP-N-helix with Cy5.5-C-25-mer. To
further validate this novel biochemical assay, we determined
the binding affinity for the interaction of MBP-N-helix with
a D-peptide: D-10-p5-2K. The Kd was 2 AM, which is
similar to the IC50 values for inhibition of syncytia
formation and cell/cell fusion previously reported (Eckert
et al., 1999).
Table 1
Binding of MBP-N-helix variants (mutants) to Cy5.5-25-mer
MBP-N-helix Kd F SD (nM) Fold increase
in Kd
WT 154 F 12 1
L568A 1600 F 70 11
V570A 400 F 18 3
W571A 1650 F 65 11
K574A 900 F 14 6
Each value was derived from two independent experiments with duplicates
for each experiment.
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C-helix
Mutations L568A, V570A, W571A, and K574A were
introduced into MBP-N-helix. No significant effects on the
expression in E. coli were observed for these mutant
proteins as a large quantity of protein was purified in all
cases. The binding affinity of the MBP-N-helix mutants
with the WT C-peptide was examined, and results are
shown in Table 1. Alanine substitutions at all four residues,
L568, V570, W571, and K574, resulted in significant loss
(at least 3-fold) of binding affinity to C-peptide. Replace-
ment of L568 or W571 with Ala resulted in the greatest loss
(11-fold) of binding affinity (Ki is 1600 nM for both
mutants) among these four mutations.
Conversely, we generated three mutants of the C-32-mer
peptide to determine the effect of amino acid replacement on
the interhelical interaction. The WT 32-mer exhibited a tight
binding to the MBP-N-helix with a Ki of 40 nM (Table 2).
Replacement of three amino acids of the C-peptide that
project toward the cavity caused a significant reduction in
the binding affinity. Specifically, W628A replacement
resulted in a 10-fold loss of activity while W631A resulted
in a 38-fold loss of affinity. Finally, I635A replacement
again resulted in a 14-fold loss of binding affinity (Table 2).
Inhibition of HIV infection by mutant C-peptides
Synthetic C-helix peptides of gp41 have been previously
shown to inhibit HIV infection and syncytium formation
(Chan and Kim, 1998; Eckert and Kim, 2001; Furuta et al.,
1998; Kilby et al., 1998). To examine the effect of mutationsTable 2
Mutants C-32-mer decreased binding to MBP-N-helix and anti-HIV-1 activity co
C-peptides Inhibition the binding of C
K i F SD (AM)
WT-32-mer
WMEWDREINNYTSLIHSLIEESQNQQEKNEQE
0.04 F 0.006
W628A-32-mer 0.39 F 0.06
W631A-32-mer 1.5 F 0.2
I635A-32-mer 0.54 F 0.04
a Fold increase compared to WT. Each value was derived from two to three indein C-peptide on the inhibition of HIV infection, we tested
the activity of the synthetic WT 32-mer C-peptide (C-32)
and three mutant peptides using an MTT assay. WT C-32
peptide had an IC50 value of 3.4 AM (Table 2). Substitutions
W628A and I635A resulted in 20- and 22-fold decrease in
activity, respectively. Mutation W631A displayed a more
dramatic loss in activity (N29-fold) as indicated by the lack
of inhibitory effect at 100 AM.
Molecular modeling of mutations
van der Waals contacts were calculated by counting all
atom–atom contacts between each side chain atom on the N-
helix residue (L568, V570, W571, and K574) to any residue
on the C-helix. Numbers of van der Waals contacts were 14
for L568, 4 for V570, 55 for W571, and 8 for K574.
Residues L568 and W571 make many more van der Waals
contacts with the C-peptide than do V570 and K574. These
two mutations also produced greater loss in Kd for binding
to C-peptide. The relationship of the seven residues studied
to the cavity is shown in Figs. 3A–C with views that vary by
908. Four residues, L568, V570, W571, and K574, form the
right wall or side chain of the hydrophobic pocket, while
three residues, W628, W631, and I635, of the C-helix
directly insert into the cavity of N-helix.Discussion
The coiled-coil domain of gp41 plays a critical role in
HIV entry. To fully validate if the prominent pocket within
this coiled-coil domain could be a potential target for the
development of small molecule inhibitors, we characterized
the role of the specific residues that are lining the side chain
and right wall of the coiled-coil pocket or others that are
inserting into this pocket on HIV gp41 with respect to their
infectivity and interhelical interaction (Figs. 1A, B). More
precisely, we assessed the capability of wild type as well as
mutant viruses to establish a productive infection by using
the standard the multiple-round of replication assay with
mutations in the context of whole HIV genome. Thus,
unlike the results from the single cycle complementation
assay or syncytium formation assay used in previousmpared to WT-32-mer
y5.5-25-mer to MBP-N-helix Anti-HIV activity
Fold increase
in Ki
a
IC50 F SD (AM) Fold
increase
in IC50
a
TD50
(AM)
1 3.44 F 0.265 1 N100
10 68.68 F 2.63 20 N100
38 N100 N29 N100
14 75.31 F 12.17 22 N100
pendent experiments with duplicates to triplicates for each experiment.
Fig. 3. Interactions of C-helix (green) and N-helix (brown) and the residues described in the mutation studies. A, B, and C are views that vary by 908.
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provide direct evidence for the importance of the residues
on viral infectivity. In addition, it has been reported that this
assay is more quantitative and more sensitive than either the
single cycle complementation assay or the syncytium
formation assay (Cao et al., 1993; Chen et al., 1998; Piller
et al., 2000), because even small amounts of virus particles
that can enter the cells would be amplified during multiple
rounds of viral replication. Our results showed that the
residues L568, V570, W571, and K574 of N-helix and
W628, W631, and I635 of C-helix are essential for
establishing a productive infection. Alanine substitution of
residues V570, W571, W628, W631, and I635 completely
abolished replication, while L568A and K574A mutants
were significantly attenuated relative to the wild type. While
other studies have previously implicated the importance of
residues L568, V570, W571, W628, W631, and I635 in
fusion activity, or mediating viral entry and/or thermal
stability of the six-helix bundle structure (Cao et al., 1993; Ji
et al., 1999; Lu et al., 2001; Wang et al., 2002; Weng and
Weiss, 1998; Weng et al., 2000), this is the first report
investigating the role of these six highly conserved residues
in the context of the entire HIV genome on the infectivity
using multiple rounds of replication assay. In addition, the
function of K574 has not previously been studied; we are
the first one reporting the reduced infectivity of this mutant.
To further investigate the interaction in detail, we
expressed and purified to homogeneity MBP-N-helix, a
fusion form of the N-helix protein, using traditional
chromatography steps. The purified protein behaves, as
expected, as a heterohexamer when combined with the C-
terminal peptide as was shown by sedimentation analysis
(data not shown). We used this form of the protein, the wild
type as well as the mutants, to develop, optimize, and
validate a novel fluorescence polarization assay, which
allowed us to assess the binding affinity between the N-
and C-helix of gp41. The assay was validated by testing a
known inhibitor cyclic D-peptide. The Kd of cyclic D-
peptide from this study agreed with the IC50 values for
inhibition of syncytia formation and cell/cell fusion that werepreviously reported (Eckert et al., 1999), suggesting that this
assay could offer a new tool for evaluation of gp41
inhibitors. Using this assay, we further demonstrated that
the reduced interhelical interaction of these seven mutants.
This is the first report demonstrating the effect of substitution
at these seven residues on direct binding between N- and C-
helix. A dramatic reduction in binding affinity was observed
between wild-type N-helix with C-peptides containing
mutation W628A, W631A, and I635A, while the greatest
loss in binding was observed with W631A (38-fold increase
in Ki). Similarly, alanine substitution at residues L568,
V570, W571, and K574 resulted in at least 3-fold loss in
binding affinity to wild-type C-peptide with a greater loss for
mutations at 568/571 than 570/574. These results correlated
well with that of molecular modeling studies. Modeling the
crystal structure of the coiled-coil domain showed that all of
the above seven residues are extensively involved in the
interhelical interaction. Among the four residues, 568, 570,
571, and 574, of N-helix, L568 and W571 make many more
van der Waals contacts with the C-peptide than do V570 and
K574. Thus, greater loss in binding potency for mutations at
positions 568/571 than 570/574 can be rationalized as
representing the greater loss of surface contact for the 568/
571 residues when substituted with Ala. Previously, muta-
tions at positions 568, 571, 628, 631, and 635 have been
shown to affect the envelope processing and/or gp120-gp41
association (Cao et al., 1993; Wang et al., 2002). In addition,
the above five mutations and the mutation at position 570
impaired the ability of envelope to mediate cell–cell fusion
(Cao et al., 1993; Ji et al., 1999; Lu et al., 2001; Wang et al.,
2002; Weng and Weiss, 1998; Weng et al., 2000). Taken
together, these findings suggest that the reduced interhelical
interaction could in part contribute to the loss of infectivity
due to these six mutations. A similar mechanism may apply
to mutation at position 574, with the caveat that the effect of
mutation K574A on the envelope processing and incorpo-
ration into virions has not been studied. Nevertheless, these
results clearly demonstrate that the interaction between the
residues comprising or packing into the pocket is essential
for the function of gp41 and HIV infectivity. Therefore,
H. Mo et al. / Virology 329 (2004) 319–327324inhibitors blocking this interaction could provide another
avenue for treatment of HIV infection.
Synthetic N- and C-terminal peptides of gp41 inhibit
HIV infection and syncytium formation (Chan and Kim,
1998; Eckert and Kim, 2001; Furuta et al., 1998; Kilby
et al., 1998). Considerable evidence indicates that these
peptides act by binding to virus gp41 and preventing the
fusogenic gp41 core formation (Chan and Kim, 1998;
Chen et al., 1993; Lu et al., 1995; Wild et al., 1994).
Here, we observed that the inhibitory activity is
dramatically reduced by C-32-mer peptides containing
single mutation W628A, W631A, or I635A (at least 20-
fold reduction compared to wild-type C-peptide). Among
these three mutant-C-32 peptides, mutant W631A
exhibited the greatest decrease in activity. These data
are also consistent with data obtained by Chan et al.
(1998) where similar amino acid replacement caused
inhibitory destabilization of similar magnitude. In their
case, the greatest destabilization was observed with
replacement of Y631A. These data correlated very well
with the results obtained using the novel fluorescence
polarization assay. These findings further support the
previous observations that the inhibitory activity of the
C-terminal peptide depends on its ability to interact with
the N-terminal coiled coil and provide additional evidence
that this interhelical interaction is critical for HIV infection.
With the majority of mutations, the level of decreased
infectivity correlated somewhat with the degree of loss in
binding affinity and the amount of van der Waals contacts,
indicating that the interhelical interaction is critical for HIV
infection. However, L568A and V570A exhibited variable
effects between the infectivity and biochemical binding.
L568A was able to establish a productive infection despite
exhibiting a large loss of van der Waals contacts and a
significant loss in binding (10-fold). In contrast, V570A
with the smallest number of van der Waals contacts and the
smallest loss in binding completely abolished infectivity.
This discrepancy may reflect potential differences in the
additional complexity of the replication assay compared
with the biochemical assay. It is likely that the replication
assay requires full formation of the N-helix/C-helix trimer–
trimer quaternary structure for successful viral replication.
Formation of lower oligomeric structures, if they occur at
all, will likely be insufficient for replication. In contrast,
since the biochemical assay uses discrete polypeptides,
some binding may additionally arise from nonhexameric
oligomeric states of uncertain composition. This cannot be
ruled out in the biochemical assay although we never
observed any allosteric behavior in the interaction between
the N- and the C-helix, which would indicate the interaction
of other forms of peptide complexes. Thus, we anticipated
that we might observe some divergence between the two
assays, and we plan to further investigate this phenomenon
in the future. This observation strengthens our conviction
that both assays should be used in a complementary way in
the drug discovery program. The inhibitors identified in thebiochemical assay will need to be validated in the
replication assay.
Here, we describe a novel fluorescence polarization
assay that can measure the direct binding of N- and C-helix
and we identified determinants of binding interaction. This
is a very simple, quantitative homogeneous fluorescence
assay that could be used in a high-throughput fashion for
the identification of HIV fusion inhibitors. We observed
that the results from this assay correlated well with data
from molecular modeling and peptide inhibition in tissue
culture, as well as with infectivity in the majority of cases.
Taken together, it suggests that the novel fluorescence
polarization assay described in this study could be a
valuable tool for identifying inhibitors that block interhel-
ical interaction and HIV replication. Interestingly, the
excitation and emission wavelength of the fluorophores
used in this assay are 665 and 725 nm, respectively, so little
spectral interference is expected from inhibitory com-
pounds. Therefore, this assay could be used successfully
to examine the inhibitory potency of compounds with
diverse spectral properties. An enzyme-linked immuno-
sorbent assay (ELISA) has been described previously that
uses a monoclonal antibody recognizing the N-helix–C-
helix dimer but not the N-helix or the C-helix separately
(Jiang et al., 1999; Liu et al., 2003). However, the novel
fluorescence polarization assay described here has several
advantages over other methods. This assay is solution-
based and it does not include extra steps for the develop-
ment of the signal. The assay can easily be adapted for
high-throughput screening of a large number of com-
pounds. A potential limitation for this assay format could
be the interaction of hydrophobic compounds with the
fluorophore (Cy5.5), which could lead to the identification
of false positive inhibitors.
Overall, our results indicate that the conserved residues
associated with the prominent pocket in the coiled coil of
HIV-1 are critical for HIV infection and interhelical
interaction, and also suggest that this pocket would be a
good target for therapeutic intervention. Our data indicate
that mutations in this region are often lethal to the virus, so
the replication of HIV mutants that are resistant to inhibitors
binding to these residues may require other compensatory
mutations. Finally, our data suggest that the novel fluo-
rescence polarization assay described here could be a
valuable assay for the identification of inhibitors that block
interhelical interaction and HIV entry.Materials and methods
Construction of mutants
To construct the PCRII-pNLEX plasmid for mutagenesis
reactions, a 3-kb EcoRI–XhoI fragment containing gp41
from HIV-1 molecular clone pNL4-3 was ligated with a TA
cloning vector. The QuikChange Site-Directed Mutagenesis
H. Mo et al. / Virology 329 (2004) 319–327 325Kit (Stratagene, La Jolla, CA) was used to create mutations
L568A, V570A, W571A, K574A, W628A, W631A, and
I631A according to the manufacturer’s instructions. The
EcoR1–XhoI segments containing the individual mutations
were cloned back into pNL4-3 to create the HIV molecular
mutant clones. DNA plasmids from the positive clones were
further confirmed by sequencing.
Construction and expression of MBP-N-helix for wild-type
(WT) and mutants
A 171-nucleotide region of N-helix (57 amino acid) was
amplified by PCR from pNL4-3 and cloned into pMAL
(New England Biolabs, Beverly, MA) such that the N-
helix was fused at the C-terminus of maltose-binding
protein (MBP). Mutants L568A, V570A, W571A, and
K574A were created using the QuikChange Site-Directed
Mutagenesis Kit (Stratagene). The WT and mutant MBP-
N-helix proteins were expressed in E. coli, and purified
using an Amylose resin column followed by an anion
exchange Q column. The purified protein behaved, as
expected, as a heterohexamer when combined with the C-
terminal peptide as was shown by sedimentation analysis
(data not shown).
Binding assay
A novel fluorescence polarization assay performed in a
96-well plate was developed. In this assay, a Cy5.5
fluorophore was coupled with C-25-mer peptide (sequence:
HTTWMEWDREINNYTSLIHSLIHSLIEES) and used as
the probe in binding assays with the purified MBP-N-helix
protein or in competition assays with unlabeled peptides and
MBP-N-helix protein. Excitation wavelength for the fluo-
rophore was set at 665 nm and emission wavelength was set
at 725 nm. Measurements were conducted in an LJL
Biosystems fluorometer (Molecular Devices, Sunnyvale,
CA) set in the fluorescence polarization mode. Data were
analyzed using an equation that calculates the direct binding
affinity (Kd) of the labeled peptide (Cy5.5-25-mer) with the
N-helix fusion protein. As for the competition assays, the Ki
values of the inhibitors were determined by using a
mathematical expression that measures the competitive
binding of two different ligands to a protein molecule
(Wang, 1995). For all of the experiments, the following
buffer was used: Dulbecco’s phosphate-buffered saline
(GibcoBRL) containing 0.1% Pluronic. In a typical experi-
ment to determine the Kd of MBP-N-helix protein with the
labeled peptide, various concentrations of MBP-N-helix
protein (5.6 nM to 10 AM) were incubated with Cy5.5-25-
mer (7.7 nM) in a 96-well plate (Corning 96 Flat Opaque
PS, Corning, NY) for 10–20 min to establish equilibrium
and the anisotropy was measured. For the competition
experiments, MBP-N-helix protein (140 nM) was preincu-
bated with various concentrations of the inhibitory peptides
(final concentration of peptide 0.003 nM to 150 AM) and 6.3nM of Cy5.5-25-mer (to obtain about 35  106 cpm
intensity).
Transfection
293-T cells at 50–70% confluency grown in 100-nm-
diameter culture plates were transfected with purified
proviral DNA (10 Ag) using the calcium phosphate method
as described previously (Mo et al., 2003) and incubated for
48 h in a CO2 incubator at 37 8C.
Infectivity assay
To determine the ability of the pNL4-3-based mutant
constructs to infect MT4 cells, supernatants from
transiently transfected 293-T cells were harvested and
filtered (0.2-Am pore size filter) at 48 h post-transfection.
The level of HIV p24 was determined using a p24-assay
kit (Abbott Laboratories, North Chicago, IL). Super-
natants containing equal amounts of p24 (1 ng/ml) were
used to infect MT4 cells. After 2-h incubation at room
temperature, the infected cells were washed with PBS
and cultured for 11 days in a CO2 incubator at 37 8C.
Every 3–4 days, the supernatants were collected and half
of the medium was replaced with fresh culture medium.
All collected supernatants were analyzed for p24
expression.
Synthesis of WT and mutant C-peptide
The 32-mer WT, W628A, W631A, and I635A mutant C-
peptides were synthesized and purified by Research
Genetics, Inc. (Huntsville, AL). All were N95% pure as
judged by mass spectroscopy.
Peptide inhibition assay
The potency of C-32-mer WT or mutant peptides in
inhibiting viral replication was determined using an MTT
assay as described previously (Molla et al., 1998). MT4
cells were resuspended to 1  105 cells/ml of medium,
seeded in a 96-well plate containing a series of half log
dilutions of peptides in medium. These cells were then
infected with HIV-1 pNL4-3 at an MOI of 0.003. All
experiments were performed in triplicate. The virus
control culture was treated in an identical manner except
no inhibitor was added to the medium. The cell control
was incubated in the absence of inhibitor or virus. Plates
were incubated for 5 days in a CO2 incubator at 37 8C.
On day 5, stock solution of MTT (4 mg/ml in PBS,
Sigma cat.# M 2128) was added to each well at 25 Al per
well. Plates were further incubated for 4 h then treated
with 20% SDS plus 0.02 N HCl at 50 Al per well to lyse
the cells. After an overnight incubation, optical density
was measured by reading the plates at 570/650 nm
wavelengths on a Bio-Tek microtitre plate reader (BIO-
H. Mo et al. / Virology 329 (2004) 319–327326TEK Instruments, Inc., Winooski, VT). Percent CPE
reduction was calculated according to the procedure
described previously (Molla et al., 1998).
Molecular modeling
Protein structure 1AIK of the six-helix core fragment of
gp41 was retrieved from the Protein Data Bank and
analyzed with Insight molecular modeling software. van
der Waals contacts were scored visually by counting all
atom–atom contacts between each side chain atom on the N-
helix residue (L568, V570, W571, and K574) to any residue
on the C-helix. Only side chain atoms beyond CG were
included, and van der Waals contacts were defined as atom–
atom distances less than 5.0 2.Acknowledgments
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